Soichiro Hozawa

Dr. Soichiro Hozawa

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Respiratory Medicine
Verified
Journal Article
Closed access
MHMarc Humbert
Marc Humbert
FAFrank C. Albers
Frank C. Albers
DBDaniel J. Bratton
Daniel J. Bratton
SYSteven W. Yancey
Steven W. Yancey
MLMark C. Liu
Mark C. Liu
NKNamhee Kwon
Namhee Kwon


1 April 2016 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SHSoichiro Hozawa
Soichiro Hozawa
MTMichikazu Terada
Michikazu Terada
YHYoshinori Haruta
Yoshinori Haruta
MHMaki Hozawa
Maki Hozawa

18 May 2021 in Journal of Asthma
Verified
Journal Article
Closed access
SHSoichiro Hozawa
Soichiro Hozawa
SMShotaro Maeda
Shotaro Maeda
AKAkira Kikuchi
Akira Kikuchi
MKMasayoshi Koinuma
Masayoshi Koinuma
Objective: Analytical studies of risk factor assessment using machine learning have recently been reported. We performed an exploratory detection study of asthma exacerbation-related factors using health insurance claims data and machine learning to explore risk factors that have high generalizability and can be easily obtained in daily practice. Methods: A dataset of asthma patients during May 2014-April 2019 from the Japanese insurance claims database, MediScope® (DB) was used. Patient characteristics and disease information were extracted, and association with occurrence of asthma exacerbation was evaluated to comprehensively search for exacerbation risk factors. Asthma exacerbations were defined as the co-occurrence of emergency medical procedures, such as emergency transport and intravenous steroid injections, with asthma claims, which were recorded in the database. Results: In total, 5,844 (13.7%) subjects had exacerbations in 42,685 eligible cases from the DB. Information on approximately 3,300 diseases was subjected to a machine learning, and 25 variables were extracted as variable importance and targeted for risk assessment. As a result, sex, days without exacerbation from cohort entry date at look-back period, Charlson Comorbidity Index, allergic rhinitis, chronic sinusitis, acute airway disease (upper airway), acute airway disease (lower airways), Chronic obstructive pulmonary disease/chronic bronchitis, gastroesophageal reflux disease, and hypertension were significantly associated with exacerbation. Dyslipidemia and periodontitis were detected as associated factors of reduced exacerbation risk. Conclusions: A comprehensive analysis of claims data using machine learning showed asthma exacerbation risk factors mostly consistent with those in previous studies. Further examination in other fields is warranted. Supplemental data for this article is available online at https://doi.org/10.1080/02770903.2021.1923740 .

1 January 2009 in Allergology International
Verified
Journal Article
Open access
SHSoichiro Hozawa
Soichiro Hozawa
YHYoshinori Haruta
Yoshinori Haruta
MTMichikazu Terada
Michikazu Terada
MYMichio Yamakido
Michio Yamakido
Whether the additive effects of the tulobuterol patch (TP), the world's first transdermal beta2-agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear. To examine the add-on effects of TP on bronchial hyperresponsiveness and reduction of the percentage of sputum eosinophils, and to compare add-on effects of TP, slow-release theophylline (SRT), and a leukotriene receptor antagonist (LTRA) in patients with asthma receiving ICS. Study 1: We randomly allocated 24 patients with asthma receiving ICS alone in equal numbers to either control treatment (ICS alone at conventional doses) or TP treatment (ICS at conventional doses plus TP at 2mg/day). Following a 2-week observation period, patients received the allocated drug regimens for 4 weeks. Methacholine challenge test and measurement of percentage of eosinophils in hypertonic saline-induced sputum were performed before and after the treatment period. Study 2: We compared add-on effects of TP, SRT, and LTRA in 65 patients with asthma receiving ICS alone, using spirometry and peak expiratory flow (PEF). Participants in these studies had experienced decrease in morning PEF to <80% of the predicted value at least twice a week. Study 1: In the TP group, improvement of bronchial hyperresponsiveness and decrease in percentage of sputum eosinophils both indicated a statistically significant difference (p < 0.01, and p < 0.05, respectively). These findings were not observed in the control group. Study 2: forced expiratory volume in 1 second (FEV(1)) and PEF markedly increased after treatment with TP compared with treatment with SRT or LTRA. These findings suggest that TP can be used as a long-term add-on controller for patients with asthma receiving ICS.

14 July 2021 in Current Medical Research and Opinion
Verified
Journal Article
Open access
YNYoichi Nakamura
Yoichi Nakamura
SHSoichiro Hozawa
Soichiro Hozawa
Hironori SagaraHironori Sagara
Hironori Sagara
HOHiroyuki Ohbayashi
Hiroyuki Ohbayashi
LLLaurie A. Lee
Laurie A. Lee
AFAndrew Fowler
Andrew Fowler
In CAPTAIN a double-blind, parallel-group, Phase IIIA study, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) improved lung function, symptoms and asthma control versus FF/VI in patients wi...